---
schema_version: "1.0.0"
document_id: "1e506ccfdf45875a7b2400d488da0ebc81e198d5a10c95ea19065975eb79c33b"
company_key: "yc-ritivel"
company: "Ritivel"
source_id: "yc-ritivel-news-import-f2b2dd915304"
canonical_url: "https://www.ritivel.com/blog/hidden-cost-ai-hallucinations-critical-documents"
published_at: "2026-01-23T00:00:00+00:00"
first_seen_at: "2026-07-23T23:10:20.911041+00:00"
fetched_at: "2026-07-28T21:58:17.349618+00:00"
content_hash: "sha256:69d4cabc9cc1fe2c40aef1f0b28cc90e2b861d2aee237eb5169b8536150e7105"
---

# The Hidden Cost of AI Hallucinations in Critical Document Creation

It's 11 PM on a Friday. Your regulatory affairs lead just opened an email from the FDA—a Complete Response letter for your CTD submission. Somewhere in those 10,000 pages, there's a citation to a clinical trial that doesn't exist. The AI that drafted Section 2.7 invented it. Now your team is pulling up the master file, scanning every reference, trying to figure out which ones are real and which are fabrications. The patent clock keeps ticking. Your competitor's application is still on track. And 50,000 patients waiting for your cancer treatment just got pushed back another six months.


This scenario isn't hypothetical. In late 2025, two major government healthcare reports were found to contain AI-generated fabrications—fake academic citations, invented court quotes, non-existent studies1,2. If it can happen to well-resourced consulting firms with layers of review, it can happen to your regulatory submission.


#### The Scale of the Problem


0.7-16.9%


Hallucination Rates


Top AI models (2025)


4.3%


Medical Domain


Average for top models


260 min/wk


Fact-Checking Time


Per knowledge worker


Sources:[Vectara Hallucination Leaderboard (2025)](https://drainpipe.io/the-reality-of-ai-hallucinations-in-2025/)


## What a Hallucination Actually Looks Like


The most dangerous hallucinations aren't the obvious ones. They're the citations that *almost* exist. Here's what your AI might generate:


⚠️


AI-Generated (Hallucinated)


"According to the Phase III trial NCT04829123 (Martinez et al., 2024), patients receiving the 200mg dose demonstrated a 47% improvement in primary endpoint response compared to placebo (p<0.001, n=342)."


✓


Reality Check


**NCT04829123** — Does not exist in ClinicalTrials.gov


**Martinez et al., 2024** — No matching publication found


**The statistics** — Synthesized from patterns in training data, not real trial results


The format looks correct. The numbers seem plausible. But none of it is real.


The trial number follows the correct format. The investigator name sounds plausible. The statistics are reasonable. But NCT04829123 doesn't exist—the AI synthesized it from patterns in its training data. A reviewer scanning quickly might miss it. An FDA examiner won't.


## The Cascade Nobody Talks About


Here's what happens when that fabricated reference slips through:


AI Hallucination


Fabricated data


FDA Review Flags


Inconsistencies detected


Complete Response


Re-submission required


Revenue Loss


Millions per day delay


Patient Impact


6-12 months delay


Your submission enters a "complete response" cycle—regulatory speak for "start over." Each day of delay costs millions3. For a drug with $2 billion in projected annual sales, a six-month delay doesn't just mean lost revenue. It means competitors capturing market share. It means physicians establishing prescribing habits with alternative treatments. It means 50,000 patients who needed your drug six months ago are still waiting—or worse, have progressed beyond the point where it could help.


## The Uncomfortable Truth About Why AI Lies


Here's something most vendors won't tell you: AI doesn't hallucinate because it's broken. It hallucinates because that's exactly what researchers trained it to do.


OpenAI's own 2025 research4 explains it bluntly: standard training procedures reward guessing over admitting uncertainty. When an AI says "I don't know," it gets penalized. When it confidently generates a plausible-sounding answer—even a wrong one—it gets rewarded. The result? Systems that would rather fabricate a clinical trial reference than leave a blank.


In medical and pharmaceutical content, this creates a perfect storm. Top AI models hallucinate 0.7%-16.9% of the time5. That's roughly once every 6 to 140 statements. In a 200-page regulatory section, you're looking at dozens of potential fabrications waiting to torpedo your submission.


#### Domain-Specific Vulnerability


General


0.8%


Technical


2.1%


Medical/Healthcare


4.3%


Legal


6.4%


Source:[Vectara Hallucination Leaderboard (2025)](https://drainpipe.io/the-reality-of-ai-hallucinations-in-2025/) . Pharmaceutical domain rates are higher due to specialized terminology, limited training data, and complex referencing systems.


Notice something counterintuitive in that chart? General content has the *lowest* hallucination rates. The more specialized your domain—legal, medical, pharmaceutical—the more likely the AI is to make things up. Why? Because regulatory language uses precise terminology that rarely appears in training data. The AI has less to work with, so it improvises. Confidently. Incorrectly.


## The Paradox You Can't Escape


So we should just avoid AI entirely, right? Here's the problem: you can't.


A CTD submission can span 10,000+ pages across all modules. Manual drafting takes months of work from multiple regulatory affairs specialists. Your competitors are already using AI. The FDA itself has recognized this reality—their January 2025 guidance6 explicitly acknowledges that AI will play a "critical role in the drug development life cycle."


The agency isn't warning companies away from AI. They're building frameworks for how to use it responsibly. That's a crucial distinction.


⚠️


The real question


You're going to use AI for your next submission—market pressure, competitive dynamics, and the FDA itself have already made that decision for you. The only question is whether you'll use it responsibly or become another cautionary tale.


## Three Things That Actually Work


The FDA's January 2025 framework7 isn't just bureaucratic checkbox exercise. It reflects hard lessons from companies that got this right—and wrong. Here's what separates them:


### 1. Ground Your AI in Reality


The technical term is "Retrieval Augmented Generation" (RAG), but here's what it actually means: instead of letting your AI generate answers from its training data (where hallucinations live), you connect it directly to verified databases—FDA regulations, ICH guidelines, your own validated trial data. Every claim the AI makes must trace back to a real source.


Think of it as the difference between asking someone to write a report from memory versus giving them access to the original documents. The AI becomes a sophisticated search-and-synthesis tool rather than a confident fabricator.


### 2. Build a Three-Question Litmus Test


Before any AI-generated content enters a critical document, your team should ask three questions:


- **Can I find this source independently?** If the AI cites NCT04829123, can you locate it in ClinicalTrials.gov?
- **Does this claim match my domain expertise?** If a statistic feels too convenient, it probably is.
- **Would I stake my signature on this?** The FDA holds people accountable, not algorithms.


This isn't about adding bureaucracy. It's about catching the 4.3% of medical content that AI gets wrong before it derails a $50 million submission.


### 3. Treat AI Validation Like Clinical Data Validation


Your organization already has rigorous processes for validating clinical trial data. AI outputs deserve the same scrutiny. Version control. Audit trails. Source documentation. If you can't trace an AI-generated statement back to its origin, it doesn't belong in your submission.


#### FDA's 7-Step Credibility Assessment Framework


Published in January 2025, this framework provides a structured approach to evaluating AI models used in regulatory submissions.


1


Define question of interest


2


Define context of use


3


Assess AI model risk


4


Develop credibility plan


5


Execute the plan


6


Document results


7


Seek FDA feedback early


Source:[FDA Draft Guidance (January 2025)](https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-product-submissions)


#### Failure Case vs. Best Practices


Aspect Failure Case Best Practice


Data Sources Untrained model, no verification RAG with verified databases (FDA, ICH, company data)


Traceability No audit trail, no source links Full provenance tracking, citation links


Human Oversight Minimal review, over-reliance on AI Structured validation checklists, expert review


Quality Control No hallucination detection Automated fact-checking, consistency validation


Regulatory Compliance No FDA framework alignment 7-step credibility assessment, early FDA engagement


## The Decision You're Already Making


Here's what I've learned from watching this space: the organizations that succeed with AI in regulatory submissions aren't the ones with the most sophisticated technology. They're the ones that treat AI like a brilliant but unreliable colleague—someone who can synthesize vast amounts of information quickly, but whose work you always verify before it goes out the door.


Your next CTD submission will use AI. That decision has already been made for you by the market, by your competitors, and by the FDA itself. The only question left: Will you be the team that catches the fabricated NCT number at 3 PM on a Tuesday, or the one explaining a Complete Response letter to your board on a Friday night?


The technology is ready. The frameworks exist. The only variable is how seriously your organization takes the gap between what AI promises and what it actually delivers.


At Ritivel, we're tackling this problem by questioning everything our AI generates—building verification into every step of the process rather than bolting it on at the end. More on how we're doing this in an upcoming post.


---


## References


1Fortune. (October 2025). "AI hallucinations found in Australian government report."[fortune.com](https://fortune.com/2025/10/07/deloitte-ai-australia-government-report-hallucinations-technology-290000-refund/)


2Fortune. (November 2025). "Fabricated AI-generated research discovered in Canadian healthcare report."[fortune.com](https://fortune.com/2025/11/25/deloitte-caught-fabricated-ai-generated-research-million-dollar-report-canada-government/)


3NBER. (2003). "The Cost of Delay in Drug Approval." Working Paper 9874.[nber.org](https://www.nber.org/system/files/working_papers/w9874/w9874.pdf)


4OpenAI. (2025). "Why Language Models Hallucinate."[openai.com](https://openai.com/index/why-language-models-hallucinate/)


5Vectara Hallucination Leaderboard. (2025). "The Reality of AI Hallucinations in 2025."[drainpipe.io](https://drainpipe.io/the-reality-of-ai-hallucinations-in-2025/)


6U.S. Food and Drug Administration. (January 2025). "Artificial Intelligence in Drug Development."[fda.gov](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development)


7U.S. Food and Drug Administration. (January 2025). "FDA Proposes Framework to Advance Credibility of AI Models."[fda.gov](https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-product-submissions)


Tags


AI


Hallucinations


FDA


Regulatory


CTD


Quality


Risk Management


Written by


### Gunin Gupta


Founder & COO


Building AI-native regulatory automation at Ritivel. Passionate about accelerating life-saving therapies through technology.
